AstraZeneca (AZN) Tops Q3 EPS by 90c, Beats on Revenue

AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $1.67, $0.90 better than the analyst estimate of $0.77. Revenue for the quarter came in at $10.98 billion versus the consensus estimate of $10.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
• Can the bull market survive surging oil prices & bond yields?
• Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial